Clinical ProgressThe AKNET platform continues to make progress in the clinic, and there is a positive sentiment towards the potential of IPH6501 due to its potential to avoid serious side effects seen in existing treatments.
Regulatory DevelopmentsLacutamab recently received breakthrough designation for relapsed or refractory Sézary syndrome, indicating clear potential for accelerated approval.
Strategic InvestmentsSanofi has agreed to invest up to €15M in equity investment in the company, which signals Sanofi’s conviction in the ANKET platform.